Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 296
- Registration Number
- NCT02351960
A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02348658
A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: TVP-1012 1mg
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 222
- Registration Number
- NCT02337764
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: TVP-1012 1mg
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 198
- Registration Number
- NCT02337751
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: TVP-1012 1mgDrug: TVP-1012 0.5mgDrug: Placebo
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 404
- Registration Number
- NCT02337738
Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Calcichew D3
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT02338713
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
Phase 2
Completed
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 164
- Registration Number
- NCT02337946
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 244
- Registration Number
- NCT02337725
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants
- First Posted Date
- 2015-01-09
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 47
- Registration Number
- NCT02334982
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus and Microalbuminuria
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 415
- Registration Number
- NCT02332824
© Copyright 2025. All Rights Reserved by MedPath